Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 9/20 | 0.67 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5092195 | 0.84 | HSD11B1 (0.78) | HSD11B1SMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL5095896 | 0.81 | HSD11B1 (0.74) | HSD11B1 | |
| SCHEMBL14301752 | 0.81 | HSD11B1 (0.74) | HSD11B1ALDH1A1 | |
| SCHEMBL5105117 | 0.81 | HSD11B1 (0.74) | HSD11B1ALDH1A1 | |
| SCHEMBL5098612 | 0.81 | HSD11B1 (0.74) | HSD11B1ALDH1A1HPGD | |
| Fig 1 SCHEMBL5095865 | 0.81 | HSD11B1 (1.00) | HSD11B1SMN1; SMN2 | |
| SCHEMBL5092127 | 0.81 | HSD11B1 (0.69) | HSD11B1ALDH1A1 | |
| SCHEMBL5095961 | 0.79 | HSD11B1 (0.71) | HSD11B1 | |
| SCHEMBL5104995 | 0.79 | HSD11B1 (0.71) | HSD11B1ALDH1A1 | |
| SCHEMBL5098044 | 0.79 | HSD11B1 (0.71) | HSD11B1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7329683-B2 | 11-β-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia | MERCK & CO., INC. (US) | 2008-02-12 | — | — | US | disclosed |
| US-7329683-B2 | 11-β-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia | MERCK & CO., INC. (US) | 2008-02-12 | — | — | US | disclosed |
| US-20050070720-A1 | 11-Beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia | MERCK SHARP & DOHME CORP. | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070720-A1 | 11-Beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia | HSD11B1, HSD17B1, HSD11B2 | HSD11B1 1/4885LRRK2 4519/4885PTGS2 1067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.